<p>Gilman Hill Asset Management LLC 在第三季度減少了對 Organon &amp; Co.（紐約證券交易所代碼：OGN - 免費報告）股票的持有，減持幅度達到 87.3%，根據其最近向證券交易委員會的披露。該公司在季度內出售了 177,746 股後，持有 25,935 股 Organon &amp; Co. 的股票。Gilman Hill Asset Management LLC 在 Organon &amp; Co. 的持股在最近的報告期末價值為 277,000 美元。</p>
<ul>
<li>默克，道瓊斯最熱門的股票，準備公佈第四季度財報</li>
</ul>
<p>其他一些機構投資者也增加或減少了對 OGN 的持股。True North Advisors LLC 在第三季度購買了價值約 158,000 美元的 Organon &amp; Co. 新頭寸。Douglas Lane &amp; Associates LLC 在第三季度將其在 Organon &amp; Co. 的持股增加了 40.5%。Douglas Lane &amp; Associates LLC 現在擁有 443,876 股該公司的股票，價值 4,741,000 美元，此前在上個季度又購買了 127,924 股。GAMMA Investing LLC 在第三季度將其在 Organon &amp; Co. 的持股增加了 22.4%。GAMMA Investing LLC 現在擁有 6,910 股該公司的股票，價值 74,000 美元，此前在上個季度又收購了 1,265 股。Osaic Holdings Inc. 在第二季度將其在 Organon &amp; Co. 的持股增加了 25.5%。Osaic Holdings Inc. 現在擁有 60,791 股該公司的股票，價值 594,000 美元，此前在上個季度又收購了 12,363 股。最後，Orion Porfolio Solutions LLC 在第二季度將其在 Organon &amp; Co. 的持股增加了 96.5%。Orion Porfolio Solutions LLC 現在擁有 63,509 股該公司的股票，價值 615,000 美元，此前在上個季度又收購了 31,190 股。對沖基金和其他機構投資者持有該公司 77.43% 的股票。</p>
<p>獲取 <strong>Organon &amp; Co.</strong> 的提醒：</p>
<h2>分析師評級變動</h2>
<p>一些券商最近對 OGN 進行了評估。摩根大通將 Organon &amp; Co. 的目標價從 14.00 美元下調至 12.00 美元，並在 11 月 11 日的報告中對該股票給予了 “減持” 評級。巴克萊在 12 月 9 日的報告中開始覆蓋 Organon &amp; Co. 的股票。他們對該股票給予了 “減持” 評級，並設定了 7.50 美元的目標價。派珀·桑德勒在 10 月 27 日的研究報告中將 Organon &amp; Co. 的股票評級從 “增持” 下調至 “減持”，並設定了 5.00 美元的目標價。摩根士丹利在 11 月 11 日的報告中將 Organon &amp; Co. 的目標價從 10.00 美元下調至 9.00 美元，並對該股票給予了 “持平” 評級。最後，Weiss Ratings 在 10 月 8 日的報告中重申了對 Organon &amp; Co. 股票的 “賣出（d+）” 評級。一位分析師對該股票給予了強烈買入評級，兩位給予了持有評級，四位給予了賣出評級。根據 MarketBeat，該公司的平均評級為 “減持”，共識目標價為 8.38 美元。</p>
<ul>
<li>Lululemon Athletica 股價因進入 S&amp;P 500 而飆升至新高</li>
</ul>
<p><strong>獲取我們關於 Organon &amp; Co. 的最新研究報告</strong></p>
<h2>Organon &amp; Co. 股價上漲 0.1%</h2>
<p>OGN 週四開盤價為 7.10 美元。該公司的市值為 18.4 億美元，市盈率為 3.70，PEG 比率為 1.52，貝塔值為 0.57。Organon &amp; Co. 的一年低點為 6.18 美元，一年高點為 17.23 美元。該公司的 50 日簡單移動平均為 7.44 美元，200 日簡單移動平均為 9.03 美元。該公司的債務與股本比率為 9.69，流動比率為 1.75，速動比率為 1.20。</p>
<p>Organon &amp; Co.（紐約證券交易所代碼：OGN - 獲取免費報告）最近一次公佈財報是在 11 月 10 日，報告顯示該公司季度每股收益為 1.01 美元，超出分析師共識預期的 0.93 美元，超出幅度為 0.08 美元。Organon &amp; Co. 的股本回報率為 143.47%，淨利潤率為 7.95%。該公司在本季度的收入為 16 億美元，而共識預期為 15.7 億美元。在去年同期，該公司的每股收益為 1.38 美元。分析師預測 Organon &amp; Co. 在當前年度的每股收益將達到 3.68 美元。</p>
<h2>Organon &amp; Co. 股息公告</h2>
<p>該公司最近還宣佈了季度股息，於 12 月 11 日支付。11 月 20 日的股東記錄將獲得每股 0.02 美元的股息。除息日期為 11 月 20 日。這相當於每年 0.08 美元的股息，股息收益率為 1.1%。Organon &amp; Co. 的股息支付比率為 4.17%。</p>
<h2>關於 Organon &amp; Co.</h2>
<p>（免費報告）</p>
<p>Organon &amp; Co. 是一家全球醫療保健公司，於 2021 年 6 月從默克公司分拆後成立為獨立的上市實體。公司總部位於新澤西州澤西市，Organon 專注於提供女性健康、生物類似藥和成熟品牌的治療解決方案。公司的創建反映了專注於具有顯著患者影響的專業藥品和傳統產品的戰略努力。</p>
<p>在女性健康領域，Organon 提供廣泛的產品組合，解決生殖和婦科疾病，包括生育治療、避孕和激素替代療法。</p>
<h2>另見</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Organon &amp; Co.</li>
<li>請勿刪除，立即閲讀</li>
<li>投資者提醒：微型 “3 美元 AI 奇蹟股票” 即將爆發</li>
<li>任何費用可以從資本利得税中扣除嗎？</li>
<li>巴菲特、蓋茨和貝索斯悄悄拋售股票——原因在這裏</li>
<li>忘掉 AI，這將是下一個重大科技突破</li>
</ul>
<p><strong>想看看其他對 OGN 持有的對沖基金嗎？</strong> 訪問 HoldingsChannel.com 獲取 Organon &amp; Co.（紐約證券交易所代碼：OGN - 免費報告）的最新 13F 文件和內部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU9HTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU9HTg"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Organon &amp; Co.嗎？</h2>
<p>在考慮 Organon &amp; Co.之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而 Organon &amp; Co.並不在名單上。</p>
<p>雖然 Organon &amp; Co.目前在分析師中被評為減持，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

<p>Gilman Hill Asset Management LLC 在第三季度減少了對 Organon & Co. 的持股，減幅達到 87.3%，目前持有 25,935 股，價值 277,000 美元。其他投資者也調整了他們的持股，分析師對 OGN 的評級各不相同。該股票開盤價為 7.10 美元，市值為 18.4 億美元。Organon 報告第三季度每股收益為 1.01 美元，超出預期，並宣佈派發 0.02 美元的股息</p>

<p>Gilman Hill Asset Management LLC lessened its holdings in shares of Organon &amp; Co. (NYSE:OGN - Free Report) by 87.3% in the third quarter, according to its most recent disclosure with the Securities &amp; Exchange Commission. The firm owned 25,935 shares of the company's stock after selling 177,746 shares during the quarter. Gilman Hill Asset Management LLC's holdings in Organon &amp; Co. were worth $277,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>Gilman Hill Asset Management LLC 在第三季度減少了對 Organon &amp; Co.（紐約證券交易所代碼：OGN - 免費報告）股票的持有，減持幅度達到 87.3%，根據其最近向證券交易委員會的披露。該公司在季度內出售了 177,746 股後，持有 25,935 股 Organon &amp; Co. 的股票。Gilman Hill Asset Management LLC 在 Organon &amp; Co. 的持股在最近的報告期末價值為 277,000 美元。</p>
</div><ul>
<li>Merck, the Dow's hottest stock, gets set to report Q4 financials</li>
</ul>
<div class="lb-trans"><ul>
<li>默克，道瓊斯最熱門的股票，準備公佈第四季度財報</li>
</ul>
</div><p>A number of other institutional investors have also added to or reduced their stakes in OGN. True North Advisors LLC purchased a new position in Organon &amp; Co. during the 3rd quarter valued at about $158,000. Douglas Lane &amp; Associates LLC grew its position in Organon &amp; Co. by 40.5% during the third quarter. Douglas Lane &amp; Associates LLC now owns 443,876 shares of the company's stock worth $4,741,000 after buying an additional 127,924 shares in the last quarter. GAMMA Investing LLC increased its stake in Organon &amp; Co. by 22.4% in the 3rd quarter. GAMMA Investing LLC now owns 6,910 shares of the company's stock worth $74,000 after acquiring an additional 1,265 shares during the last quarter. Osaic Holdings Inc. increased its stake in Organon &amp; Co. by 25.5% in the 2nd quarter. Osaic Holdings Inc. now owns 60,791 shares of the company's stock worth $594,000 after acquiring an additional 12,363 shares during the last quarter. Finally, Orion Porfolio Solutions LLC raised its holdings in shares of Organon &amp; Co. by 96.5% in the 2nd quarter. Orion Porfolio Solutions LLC now owns 63,509 shares of the company's stock valued at $615,000 after acquiring an additional 31,190 shares in the last quarter. Hedge funds and other institutional investors own 77.43% of the company's stock.</p>
<div class="lb-trans"><p>其他一些機構投資者也增加或減少了對 OGN 的持股。True North Advisors LLC 在第三季度購買了價值約 158,000 美元的 Organon &amp; Co. 新頭寸。Douglas Lane &amp; Associates LLC 在第三季度將其在 Organon &amp; Co. 的持股增加了 40.5%。Douglas Lane &amp; Associates LLC 現在擁有 443,876 股該公司的股票，價值 4,741,000 美元，此前在上個季度又購買了 127,924 股。GAMMA Investing LLC 在第三季度將其在 Organon &amp; Co. 的持股增加了 22.4%。GAMMA Investing LLC 現在擁有 6,910 股該公司的股票，價值 74,000 美元，此前在上個季度又收購了 1,265 股。Osaic Holdings Inc. 在第二季度將其在 Organon &amp; Co. 的持股增加了 25.5%。Osaic Holdings Inc. 現在擁有 60,791 股該公司的股票，價值 594,000 美元，此前在上個季度又收購了 12,363 股。最後，Orion Porfolio Solutions LLC 在第二季度將其在 Organon &amp; Co. 的持股增加了 96.5%。Orion Porfolio Solutions LLC 現在擁有 63,509 股該公司的股票，價值 615,000 美元，此前在上個季度又收購了 31,190 股。對沖基金和其他機構投資者持有該公司 77.43% 的股票。</p>
</div><p>Get <strong>Organon &amp; Co.</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Organon &amp; Co.</strong> 的提醒：</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><p>A number of brokerages recently weighed in on OGN. JPMorgan Chase &amp; Co. decreased their price objective on Organon &amp; Co. from $14.00 to $12.00 and set an &#34;underweight&#34; rating on the stock in a report on Tuesday, November 11th. Barclays assumed coverage on shares of Organon &amp; Co. in a report on Tuesday, December 9th. They set an &#34;underweight&#34; rating and a $7.50 target price on the stock. Piper Sandler lowered shares of Organon &amp; Co. from an &#34;overweight&#34; rating to an &#34;underweight&#34; rating and set a $5.00 price target for the company. in a research report on Monday, October 27th. Morgan Stanley decreased their price objective on Organon &amp; Co. from $10.00 to $9.00 and set an &#34;equal weight&#34; rating on the stock in a report on Tuesday, November 11th. Finally, Weiss Ratings restated a &#34;sell (d+)&#34; rating on shares of Organon &amp; Co. in a report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Hold rating and four have issued a Sell rating to the company's stock. According to MarketBeat, the company has an average rating of &#34;Reduce&#34; and a consensus target price of $8.38.</p>
<div class="lb-trans"><p>一些券商最近對 OGN 進行了評估。摩根大通將 Organon &amp; Co. 的目標價從 14.00 美元下調至 12.00 美元，並在 11 月 11 日的報告中對該股票給予了 “減持” 評級。巴克萊在 12 月 9 日的報告中開始覆蓋 Organon &amp; Co. 的股票。他們對該股票給予了 “減持” 評級，並設定了 7.50 美元的目標價。派珀·桑德勒在 10 月 27 日的研究報告中將 Organon &amp; Co. 的股票評級從 “增持” 下調至 “減持”，並設定了 5.00 美元的目標價。摩根士丹利在 11 月 11 日的報告中將 Organon &amp; Co. 的目標價從 10.00 美元下調至 9.00 美元，並對該股票給予了 “持平” 評級。最後，Weiss Ratings 在 10 月 8 日的報告中重申了對 Organon &amp; Co. 股票的 “賣出（d+）” 評級。一位分析師對該股票給予了強烈買入評級，兩位給予了持有評級，四位給予了賣出評級。根據 MarketBeat，該公司的平均評級為 “減持”，共識目標價為 8.38 美元。</p>
</div><ul>
<li>Lululemon Athletica Races to New High with S&amp;P 500 Entry</li>
</ul>
<div class="lb-trans"><ul>
<li>Lululemon Athletica 股價因進入 S&amp;P 500 而飆升至新高</li>
</ul>
</div><p><strong>Get Our Latest Research Report on Organon &amp; Co.</strong></p>
<div class="lb-trans"><p><strong>獲取我們關於 Organon &amp; Co. 的最新研究報告</strong></p>
</div><h2>Organon &amp; Co. Trading Up 0.1%</h2>
<div class="lb-trans"><h2>Organon &amp; Co. 股價上漲 0.1%</h2>
</div><p>OGN opened at $7.10 on Thursday. The firm has a market capitalization of $1.84 billion, a price-to-earnings ratio of 3.70, a PEG ratio of 1.52 and a beta of 0.57. Organon &amp; Co. has a one year low of $6.18 and a one year high of $17.23. The business has a 50 day simple moving average of $7.44 and a two-hundred day simple moving average of $9.03. The company has a debt-to-equity ratio of 9.69, a current ratio of 1.75 and a quick ratio of 1.20.</p>
<div class="lb-trans"><p>OGN 週四開盤價為 7.10 美元。該公司的市值為 18.4 億美元，市盈率為 3.70，PEG 比率為 1.52，貝塔值為 0.57。Organon &amp; Co. 的一年低點為 6.18 美元，一年高點為 17.23 美元。該公司的 50 日簡單移動平均為 7.44 美元，200 日簡單移動平均為 9.03 美元。該公司的債務與股本比率為 9.69，流動比率為 1.75，速動比率為 1.20。</p>
</div><p>Organon &amp; Co. (NYSE:OGN - Get Free Report) last announced its earnings results on Monday, November 10th. The company reported $1.01 EPS for the quarter, beating analysts' consensus estimates of $0.93 by $0.08. Organon &amp; Co. had a return on equity of 143.47% and a net margin of 7.95%.The company had revenue of $1.60 billion during the quarter, compared to the consensus estimate of $1.57 billion. During the same quarter in the prior year, the company earned $1.38 earnings per share. Analysts predict that Organon &amp; Co. will post 3.68 EPS for the current year.</p>
<div class="lb-trans"><p>Organon &amp; Co.（紐約證券交易所代碼：OGN - 獲取免費報告）最近一次公佈財報是在 11 月 10 日，報告顯示該公司季度每股收益為 1.01 美元，超出分析師共識預期的 0.93 美元，超出幅度為 0.08 美元。Organon &amp; Co. 的股本回報率為 143.47%，淨利潤率為 7.95%。該公司在本季度的收入為 16 億美元，而共識預期為 15.7 億美元。在去年同期，該公司的每股收益為 1.38 美元。分析師預測 Organon &amp; Co. 在當前年度的每股收益將達到 3.68 美元。</p>
</div><h2>Organon &amp; Co. Dividend Announcement</h2>
<div class="lb-trans"><h2>Organon &amp; Co. 股息公告</h2>
</div><p>The company also recently announced a quarterly dividend, which was paid on Thursday, December 11th. Shareholders of record on Thursday, November 20th were issued a dividend of $0.02 per share. The ex-dividend date was Thursday, November 20th. This represents a $0.08 dividend on an annualized basis and a dividend yield of 1.1%. Organon &amp; Co.'s dividend payout ratio is 4.17%.</p>
<div class="lb-trans"><p>該公司最近還宣佈了季度股息，於 12 月 11 日支付。11 月 20 日的股東記錄將獲得每股 0.02 美元的股息。除息日期為 11 月 20 日。這相當於每年 0.08 美元的股息，股息收益率為 1.1%。Organon &amp; Co. 的股息支付比率為 4.17%。</p>
</div><h2>About Organon &amp; Co.</h2>
<div class="lb-trans"><h2>關於 Organon &amp; Co.</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Organon &amp; Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck &amp; Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.</p>
<div class="lb-trans"><p>Organon &amp; Co. 是一家全球醫療保健公司，於 2021 年 6 月從默克公司分拆後成立為獨立的上市實體。公司總部位於新澤西州澤西市，Organon 專注於提供女性健康、生物類似藥和成熟品牌的治療解決方案。公司的創建反映了專注於具有顯著患者影響的專業藥品和傳統產品的戰略努力。</p>
</div><p>In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.</p>
<div class="lb-trans"><p>在女性健康領域，Organon 提供廣泛的產品組合，解決生殖和婦科疾病，包括生育治療、避孕和激素替代療法。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Organon &amp; Co.</li>
<li>Do not delete, read immediately</li>
<li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li>
<li>Can Any Expenses Be Deducted From Capital Gains Tax?</li>
<li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li>
<li>Forget AI, This Will Be the Next Big Tech Breakthrough</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Organon &amp; Co.</li>
<li>請勿刪除，立即閲讀</li>
<li>投資者提醒：微型 “3 美元 AI 奇蹟股票” 即將爆發</li>
<li>任何費用可以從資本利得税中扣除嗎？</li>
<li>巴菲特、蓋茨和貝索斯悄悄拋售股票——原因在這裏</li>
<li>忘掉 AI，這將是下一個重大科技突破</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding OGN?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Organon &amp; Co. (NYSE:OGN - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對 OGN 持有的對沖基金嗎？</strong> 訪問 HoldingsChannel.com 獲取 Organon &amp; Co.（紐約證券交易所代碼：OGN - 免費報告）的最新 13F 文件和內部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU9HTg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=OGN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Organon &amp; Co. Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Organon &amp; Co.嗎？</h2>
</div><p>Before you consider Organon &amp; Co., you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Organon &amp; Co.之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organon &amp; Co. wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而 Organon &amp; Co.並不在名單上。</p>
</div><p>While Organon &amp; Co. currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Organon &amp; Co.目前在分析師中被評為減持，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Gilman Hill Asset Management LLC 減少了其在 Organon & Co. $OGN 的持倉